| Literature DB >> 11150532 |
T Miyazaki1, I Matsuda, M Oguri, H Amaya, M Kiyosaki, A Hamada, S Tamaki, E Tashiro, Y Kudo, O Taniguchi, T Nakamura, S Tomoyasu.
Abstract
We analyzed CD34 positive cells in peripheral blood stem cell harvest (PBSCH) using flow cytometry. PBSCH from CD34 positive acute myelogeous leukemia (AML-M2) patient contained 1.87% CD34 positive cells, of which 1.21% was represented by MRD.PBSCH from CD34 positive acute lymphoblast leukemia (ALL) patient contained 3.14% CD34 positive cells, of which 0.11% was accounted for by minimal residual disease (MRD). If PBSCH from CD34 positive acute leukemia patient is analyzed for CD34 monoclonal antibody alone, the presence of CD34 positive MRD may escape attention so that CD34 positive hematopoietic progenitor cells may be overestimated. To avoid this risk, it is necessary to analyze PBSCH using both CD34 monoclonal antibody and characteristic markers of leukemia cells that were found pre-treatment.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11150532 DOI: 10.1016/s0022-1759(00)00315-x
Source DB: PubMed Journal: J Immunol Methods ISSN: 0022-1759 Impact factor: 2.303